Anoop, A, Singh, PK, Jacob, RS, et al. (2010) CSF biomarkers for Alzheimer's disease diagnosis. International Journal of Alzheimer's Disease, 2010: article ID 606802.
Bacskai, B, Frosch, J, Freeman, M, et al. (2007) Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Archives of Neurology, 64: 431–4.
Bennett, DA, Schneider, JA, Wilson, RS, et al. (2004) Neurofibrillary tangles mediates the association of amyloid load with clinic Alzheimer disease and level of cognitive function. Archives of Neurology, 61: 378–84.
Berti, V, Polio, C, Lombardi, G, et al. (2016) Rethinking on the concept of biomarkers in preclinical Alzheimer's disease. Neurological Sciences, 37: 663–72.
Chetelat, G, Villemagne, VL, Pike, K, et al. (2011) Independent contribution of temporal b-amyloid deposition to memory decline in non-demented elderly. Brain, 134: 798–807.
De Meyer, G, Shapiro, F, Vanderstichele, H, et al. (2010) Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Archives of Neurology, 67: 949–56.
De Souza, LC, Lamari, F, Belliard, S, et al. (2011) Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. Journal of Neurology, Neurosurgery, and Psychiatry, 82: 240–6.
Dubois, B, Albert, ML (2004) Amnestic MCI or prodromal Alzheimer's disease? Lancet Neurology, 3: 246–8.
Dubois, B, Feldman, H, Jacova, C, et al. (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurology, 6: 734–46.
Dubois, B, Feldman, HH, Jacova, C, et al. (2014) Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, 13: 614–29.
Estes, CL, Binney, EA (1989) The biomedicalization of aging: dangers and dilemmas. Gerontologist, 29: 587–96.
Fagan, A, Mintum, M, Mach, R, et al. (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Annals of Neurology, 59: 512–9.
Fagan, AM, Roe, CM, Xiong, C, et al. (2007) Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Archives of Neurology, 64: 343–9.
Green, R, Roberts, J, Cupples, L, et al. (2009) Disclosure of APOE genotype for risk of Alzheimer's disease. New England Journal of Medicine, 361: 245–54.
Hansson, O, Zetterberg, H, Buchhave, P et al. (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurology, 5: 228–34.
Hardy, J, Selkoe, DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297: 353–6.
Harkins, K, Sankar, P, Sperling, R, et al. (2015) Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimer's Research & Therapy, 7: 26.
Herskovits, Z, Growden, J (2010) Sharpen that needle. Archives of Neurology, 67: 918–20.
Hughes, J, Ingram, T, Jarvis, A, et al. (2017) Consent for the diagnosis of preclinical dementia states: a review. Maturitas, 98: 30–4.
Jack, CR Jr, Albert, MS, Knopman, DS, et al. (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7: 257–62.
Jack, CR Jr, Knopman, DS, Jagust, WJ, et al. (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lanet Neurology, 9: 119–28.
Klein, WL, Stine, WB Jr, Teplow, DB (2004) Small assemblies of unmodified amyloid beta protein are the proximate neurotoxin in Alzheimer's disease. Neurobiology of Aging, 25: 569–80.
Koopman, K, Le Bastard, N, Martin, JJ, et al. (2009) Improved discrimination of autopsy-confirmed Alzheimer's disease from non-AD dementias using CSF P-tau. Neurochemistry International, 55: 214–8.
Li, G, Sokal, I, Quinn, JF, et al. (2007) CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology, 69: 631–9.
Lim, J, Li, Q, He, Z, et al. (2016) The eye as a biomarker for Alzheimer's disease. Frontiers in Neuroscience, 10: 536.
Livingston, G, Sommerlad, A, Orgeta, V, et al. (2017) Dementia prevention, intervention, and care. Lancet, 390: 2673–734.
Mattsson, N, Zetterberg, H, Hansson, O, et al. (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA, 302: 385–93.
Mattsson, N, Andreasson, U, Persson, S, et al. (2013) CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's & Dementia, 9: 251–61.
McKhann, G, Drachman, D, Folstein, M, et al. (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 34: 939–44.
Morris, JC, Storandt, M, McKeel, DW Jr, et al. (1996) Cerebral amyloid deposition and diffuse plaques in ‘normal’ aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology, 46: 707–19.
Morris, JC, Roe, CM, Grant, EA, et al. (2009) Pittsburgh Compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Archives of Neurology, 66: 1469–75.
Nakamura, A, Kaneko, N, Villemagne, VL, et al. (2018) High performance plasma amyloid-β biomarkers for Alzheimer's disease. Nature, 554: 249–54.
Parnetti, L, Lanari, A, Silvestrelli, G, et al. (2006) Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers. Mechanisms of Ageing and Development, 127: 129–32.
Prince, M, Comas-Herrera, A, Knapp, M, et al. (2016) World Alzheimer Report 2016: Improving Healthcare for People Living with Dementia. Coverage, Quality and Costs Now and in the Future. Alzheimer‘s Disease International.
Resnick, SM, Sojkova, J, Zhou, Y, et al. (2010) Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology, 74: 807–15.
Shivamurthy, V, Tahari, A, Marcus, C, et al. (2015) Brain FDG PET and the diagnosis of dementia. Nuclear Medicine and Molecular Imaging, 204: 76–85.
Snider, BJ, Fagan, AM, Roe, C, et al. (2009) Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Archives of Neurology, 66: 638–45.
Sperling, RA, Aisen, PS, Beckett, LA, et al. (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia, 7: 280–92.
Stern, Y (2012) Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurology, 11: 1006–12.
Storandt, M, Mintun, MA, Head, D, et al. (2009) Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Archives of Neurology, 66: 1476–81.
Tapiola, T, Alafuzoff, I, Herukka, SK, et al. (2009) Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Archives of Neurology, 66: 382–9.
Van Rossum, IA, Vos, S, Handels, R, et al. (2010) Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. Journal of Alzheimer's Disease, 20: 881–91.
Vemuri, P, Wiste, HJ, Weigand, SD, et al. (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology, 73: 294–301.
Villemagne, VL, Pike, KE, Darby, D, et al. (2008) Aß deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia, 46: 1688–97.
Visser, PJ, Verhey, F, Knol, D, et al. (2009) Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurology, 8: 619–27.
Watkin, A, Sikdar, S, Majurndar, B, et al. (2013) New diagnostic concepts in Alzheimer's disease. BJPsych Advances, 19: 242–9.
Wilson, JMG, Jungner, G (1968) Principles and Practice of Screening for Disease (Public Health Papers 34). World Health Organization.
Yaffe, K, Weston, A, Graff-Radford, NR, et al. (2011) Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA, 305: 261–6.